GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
-
Published:2024-09
Issue:
Volume:75
Page:102782
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Alfaris NasreenORCID,
Waldrop Stephanie,
Johnson Veronica,
Boaventura BrunnaORCID,
Kendrick KarlaORCID,
Stanford Fatima CodyORCID
Reference89 articles.
1. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021;Ong;Lancet,2023
2. Global impact of obesity;Alfaris;Gastroenterol Clin,2023
3. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials;Sattar;Lancet Diabetes Endocrinol,2021
4. Physiological integration of taste and metabolism;Egan;N Engl J Med,2024
5. Mechanisms of action and therapeutic application of glucagon-like peptide-1;Drucker;Cell Metabol,2018